Enterococcal superinfection and colonization with aztreonam therapy.
Patients were given aztreonam (SQ 26,776) parenterally for the treatment of various gram-negative infections. During or shortly after therapy, 8 (17.8%) of 45 patients became infected with or colonized by enterococcus. These eight cases included eight urinary tract isolates; one of these cases subsequently developed bacteremia. Five patients required further antimicrobial therapy directed against enterococcus. Patients receiving aztreonam are at risk for the development of enterococcal superinfection or colonization.
D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D001398:Aztreonam; D006801:Humans; D013290:Streptococcal Infections / Q000209:etiology* / Q000382:microbiology; D013291:Streptococcus / Q000254:growth & development
D000900:Anti-Bacterial Agents; D001398:Aztreonam